[
    "{\"step_by_step_thinking\": \"Based on the provided documents, we can gather the following information:\\n- Dexmecamylamine is a nicotinic channel modulator that has been evaluated as a potential adjunct treatment for major depressive disorder (MDD).\\n- Document [0] reports the long-term safety and tolerability of dexmecamylamine in patients with MDD and inadequate response to antidepressants. It mentions that safety and tolerability were consistent with that reported in acute Phase III studies of dexmecamylamine.\\n- Document [2] reports the efficacy and tolerability of dexmecamylamine as adjunct therapy for patients with MDD who have an inadequate response to initial antidepressant treatment. It states that no specific therapeutic effects were observed for dexmecamylamine in the primary or secondary endpoints.\\n- Document [7] discusses the population pharmacokinetics of TC-5214 (dexmecamylamine) and its evaluation for the treatment of MDD.\\n- Document [17] mentions dexmecamylamine as a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders.\\n\\nBased on this information, the answer to the question \\\"Is Dexmecamylamine effective for depression?\\\" is:\\nB. no\", \"answer_choice\": \"B\"}"
]